Recherche sur les fragments ARN
Un faible nombre de plaquettes, une condition appelée thrombocytopénie, est un effet secondaire des médicaments chimiothérapeutiques qui endommagent les cellules souches de la moelle osseuse qui produisent normalement des plaquettes. Cet essai de phase I a montré que les fragments d’ARN de Beljanski pouvaient prévenir la thrombocytopénie en induisant la production de nouvelles plaquettes. Les patients prenant les fragments d’ARN ont eu leurs taux de plaquettes revenir à la normale et les traitements de chimiothérapie ont été terminés sans réduction de dose, transfusion de plaquettes ou suspensions. Les fragments d’ARN protégeaient les taux plaquettaires des patients atteints de nombreux types de cancer qui prenaient des médicaments anticancéreux différents en grand nombre. De plus, ces patients n’ont pas subi d’effets secondaires négatifs à la suite de la prise des fragments d’ARN contrairement aux malades n’en ayant pas reçu.
ABSTRACT: Cell function and differentiation are the outcome of multiple and complex events. Information contained in the genes is transferred to the enzymes and machinery responsible for protein synthesis via sophisticated biochemical pathways, some of which, despite their intricacy, are now well documented. Conversely, genes receive information which modulates their activity. Many different molecules are able to bind to nucleic acids (deoxyribonucleic acid, DNA, and ribonucleic acid, RNA), thereby modifying gene activity as well as that of various enzymes connected with it. It is well established that the effect of endogenous or exogenous molecules on such fundamental processes of cell life as DNA duplication, transcription and translation may dramatically affect other biochemical processes both downstream and upstream. Binding of any molecule to DNA may influence cell life “for better or for worse”.
Les publications de Mirko Beljanski
Pendant qu’il développait ses extraits, le Dr Mirko Beljanski a nommé le Pao pereira: PB100, le Rauwolfia vomitoria: BG-8, le Gingko Biloba: Bioparyl et les fragments d’ARN: RLB
79 / BELJANSKI, M. PLAWECKI, P. BOURGAREL, M. S. BELJANSKI, “Nouvelles substances (R.L.B.) actives dans la leucopoïese et la formation des plaquettes“. Bull. Acad. Nat. Med., 1978, 162, Volume n°6, pp. 475-781.
83 / BELJANSKI, M. PLAWECKI, “Particular RNA Fragments as Promoters of Leukocytes and Platelets Formations in Rabbits“. Exp. Cell Biol., 1979, 47, pp. 218-225.
86 / BELJANSKI, “Oligoribo-nucleotides, promoters of leucocyte and platelet genesis in animals depleted by anticancer drugs”. NCI-EORTC Symposium on nature, prevention and treatment of clinical toxicity of anticancer agents. Institut Bordet, Bruxelles, 1980.
87 / BELJANSKI, M. PLAWECKI, P. BOURGAREL, M.S. BELJANSKI, “Short chain RNA fragments as promoters of leucocyte and platelet genesis in animals depleted by anti-cancer drugs”. In the Role of RNA in Development and Reproduction. Sec. Int. Symposium, april 25-30, 1980, pp.79-113. Science Press Beijing. M.C. Niu and H.H. Chuang Eds Van Nostrand Reinhold Company.
118 / DONADIO, R. LORHO, J.E. CAUSSE, T. NAWROCKI, M. BELJANSKI,” RNA Fragments (RLB) and Tolerance of CytostaticTreatments in Hematology:A Preliminary Study about Two Non-Hodgkin Malignant Lymphoma Cases“. Deutsche Zeitschrift für Onkologie, 23, 2, 1991, pp. 33-35.
119 / BELJANSKI, ” Reverse Transcriptases in Bacteria: Small RNAs as Genetic Vectors and Biological Modulators “. Brazil. J. Genetics, 14, 4, 1991, pp. 873-896.
120 / BELJANSKI, “Radioprotection of Irradiated Mice – Mechanisms and Synergistic Action of WR-2721 and R.L.B.”. Deutsche Zeitschrift für Onkologie, 23, 6, 1991, pp. 155-159.
121 / BELJANSKI, ” Overview: BLRs as Inducers of In Vivo Leucocyte and Platelet Genesis “. Deutsche Zeitschrift für Onkologie, 24, 2, 1992, pp. 41-46.
